GLP-1 Orforglipron 10 mg 60 caps

Orforglipron 10 mg: Product Information

Orforglipron 10 mg It is a non-peptide investigational compound classified as a GLP-1 receptor (GLP-1R) agonist, also referred to in the scientific literature as LY3502970. Unlike classical GLP-1 analogs based on a peptide structure, orforglipron is a small-molecule synthetic ligand, which makes it an interesting subject for research into incretin signaling, G-protein-coupled receptors (GPCRs), and the properties of non-peptide GLP-1R agonists.

Orforglipron has the molecular formula C₄₈H₄₈F₂N₁₀O₅, a molecular weight of 882.96 g/mol, and CAS number 2212020-52-3. As a non-peptide compound, it does not possess the amino acid sequence characteristic of the peptides under study. In scientific publications, it is noted primarily for its chemical stability, its ability to interact with the GLP-1R receptor without a peptide structure, and its high selectivity toward the molecular target under study. The declared purity of the product is ≥99% HPLC, which allows the material to be used in qualitative analyses, comparative studies, and reference procedures.

Research on orforglipron

Orforglipron has attracted significant interest from the scientific community due to its activity against the GLP-1R receptor and its research potential in the field of metabolism and energy balance regulation. Published studies have analyzed its effects on signaling pathways related to glucose metabolism, appetite control, and the mechanisms involved in maintaining body weight.

In the scientific literature, orforglipron is described as one of the most advanced non-peptide GLP-1R agonists, which has made it the subject of numerous studies on metabolic processes and the physiology of the incretin system. Preclinical and clinical analyses have demonstrated the activation of biological pathways characteristic of GLP-1 receptors, making this compound widely used as a reference standard in research projects related to metabolism, energy homeostasis, and the regulation of food intake.

The growing number of scientific publications on orforglipron makes it one of the most frequently studied small-molecule GLP-1R agonists today, serving as a valuable tool for research into the mechanisms regulating body weight, incretin signaling, and the function of G-protein-coupled receptors.

Scientific sources:

1. Kawai et al., PNAS - A structural study describing the mechanism of GLP-1 receptor activation by the non-peptide agonist LY3502970 / orforglipron and its GLP-1R partial agonist profile.
2. Pratt et al, Diabetes, Obesity and Metabolism / PubMed - A publication on orforgliprone as a new oral, non-peptide GLP-1 receptor agonist being analyzed in a phase 2 study.
3. Wharton et al., New England Journal of Medicine - A phase 2 study describing orforglipron as an oral GLP-1 receptor agonist analyzed in adult subjects.
4. PubChem / ChEMBL - chemical bases confirming the basic identification data of the compound, including CAS number, sum formula and molecular weight of orforgliprone